Disclosure of Shareholdings

EQS Voting Rights Announcement: BB BIOTECH AG Disclosure of Shareholdings 23.06.2025 / 07:00 CET/CEST Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Disclosure of Shareholdings Submited, 18/06/2026

 

Notification ID: 77b1d1cb-63b3-4b8f-b0f1-bb767e0006e7

 

Disclosure notification concerning a single investor
Name of listed company

BB Biotech AG
 

PART 1: PERSON SUBJECT TO REPORTING OBLIGATION

Last name, first name, place of residence or company name and head office of the beneficial owner (art. 120 para. 1 FMIA) and/ or of the person who has the discretionary power to exercise the voting rights (art. 120 para. 3 FMIA):

Company: Saba Capital Management, L.P

City: New York

Country: United States of America (the)

 

PART 2: IN CASE OF INDIRECT PARTICIPATION

Last name, first name, place of residence or company name and head office of the person/s directly involved

 

PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION

Date of the act that creates the obligation to notify: 17.06.2025

Facts and circumstances triggering the obligation to notify (art. 22 para. 1 b FMIO-FINMA):

X Acquisition

Sale

Creation of a group

Change in group composition Termination of a group

Discretionary exercise of voting rights

Securities lending and comparable transactions

Exercise, non-exercise or expiration of derivative holdings

Granting (writing) of derivative holdings

Capital increase

Capital reduction

Ipso jure transfer or transfer due to a decision by a court or public authority

Change in the information subject to the obligation to notify

Other 


Total of voting rights below 3%

If the participation falls below the threshold of 3% (purchase positions and sale positions), no indication in Part 4 or Part 5 is required.

Total of voting rights <3%

 

PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA

 

Total of all purchase positions:

Total of all equity securities or equity related securities (item 1), number of voting rights that can be exercised at one’s own discretion (item 3) and derivative holdings (item 4)

Number of voting rights	Percentage
S1 = [1.1] + [3.1] + [4.1]	S2 = [1.2] + [3.2] + [4.2]
1,697,636	3.064%

 

Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:

 55,400,000 
 

1. Equity securities or equity related securities

 

Shares	Number	Voting rights1
		Number	Percentage2
Registered share	503,638	503,638	0.909%
Total		[1.1] 503,638	[1.2] 0.909%

1. Whether exercisable or not
2. Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

 

2. Securities lending and comparable transactions in equity securities

Of the equity securities mentioned in item 1 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):

 

Shares

Number

Proportion of voting rights

Nature of the legal transaction

Agreed date of return transfer or, if there is a right to choose, whether this applies to the contracting party subject to the obligation to notify or to the counterparty

 

3. Voting rights that can be exercised at one's own discretion

The following voting rights were delegated by a third party and can be exercised at one's own discretion.

 

Voting rights

Is the person who has full discretionary powers to exercise voting rights directly or indirectly controlled?

Yes  No

 

4. Derivative holdings

Conversion and share purchase rights (such as call-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) share sale rights and other derivative holdings:

 

Type of rights	Number of rights	Number of voting rights conferred		Security ID number (ISIN) if available or basic terms
		Number	Percentage2	Identity of issuer, subscription ratio, exercise price, exercise period, exercise type
CFD	1,193,998	1,193,998	2.155%	CH0038389992
		[4.1]	[4.2]
Total		1,193,998	2.155%

2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

 

5. Securities lending and comparable transactions in derivative holdings

Of the derivative holdings mentioned in item 4 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):

 

Nature of the legal transaction

Number of rights

Number of reported voting rights

Proportion of voting rights

Agreed date of return transfer or, if there is a right to choose, whether this applies to the contracting party subject to the obligation to notify or to the counterparty

PART 5: SALE POSITIONS PURSUANT TO ART. 14 PARA. 1 B FMIO-FINMA

Total of all sale positions: 
Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:

 55,400,000 

 

Derivative holdings

Share sale rights (such as put-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) conversion and share purchase rights and other derivative holdings:

 

Type of rights	Number of rights	Number of voting rights conferred		Security ID number (ISIN) if available or basic terms
		Number	Percentage2	Identity of issuer, subscription ratio, exercise price, exercise period, exercise type

Total

2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

---

23.06.2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---

Language:	English
Company:	BB BIOTECH AG
	Schwertstrasse 6
	8200 Schaffhausen
	Switzerland
Internet:	www.bbbiotech.ch

End of News	EQS News Service

2158408  23.06.2025 CET/CEST